Showing 5161-5170 of 10417 results for "".
- FDA Approves First Topical Gene Therapy for Treatment of Wounds in Patients with DEBhttps://practicaldermatology.com/news/fda-approves-first-topical-gene-therapy-for-treatment-of-wounds-in-patients-with-deb/2461732/The U.S. Food and Drug Administration approved Vyjuvek, a herpes-simplex virus type 1 (HSV-1) vector-based gene therapy, for the treatment of wounds in patients 6 months of age and older with dystrophic epidermolysis bullosa (DEB) with mutation(s) in the collagen type VII alpha 1 chain (COL7A1) g
- Oral IL-23 Receptor Antagonist Makes Waves in Tokyohttps://practicaldermatology.com/news/oral-il-23-receptor-antagonist-makes-waves-in-tokyo/2461716/Protagonist Therapeutics and Janssen Biotech, Inc.'s oral IL-23 receptor antagonist, JNJ-2113, performed well in Phase 1 and Pre-clinical Studies. JNJ-2113 is a macrocyclic peptide that binds to the IL-23 receptor with single digit picomolar affinity and demonstr
- Cutera Update: Agreements Made With Pura Vida and RTW; New Board Members Appointedhttps://practicaldermatology.com/news/cutera-update-agreements-made-with-pura-vida-and-rtw-new-board-members-appointed/2461712/Cutera announced that it has entered into cooperation agreements with two of its largest stockholders, Pura Vida Investments LLC and RTW Investments LP, which collectively own more than 15% of the company’s outstanding shares. Pursuant to the agreements, Cutera will appo
- Cytrellis Taps New CTOhttps://practicaldermatology.com/news/cytrellis-taps-new-cto/2461695/Dr. Shiv Sabesan is Cytrellis Biosystems’ Chief Technology Officer. In his new role, Dr. Sabesan will lead the company's strategy as it continues to advance its proprietary ellacor Micro-Coring technology and expand indications. The technology was
- Cetaphil Teams Up with Makeup Artist Alexx Mayo for Lizzo's Upcoming Tourhttps://practicaldermatology.com/news/cetaphil-teams-up-with-makeup-artist-alexx-mayo-for-lizzos-upcoming-tour/2461684/Cetaphil cleansers and moisturizers will be an integral part of Lizzo’s skin prep and glam during her upcoming "Special" tour courtesy of makeup artist Alexx Mayo. The brand will enlist Alexx Mayo to create social content showcasing how he relies on
- Cynosure Taps New CEOhttps://practicaldermatology.com/news/cynosure-taps-new-ceo/2461676/Nadav Tomer is Cynosure’s new chief executive officer, effective May 1, 2023. He succeeds Todd Tillemans, who will step down and will work closely with Mr. Tomer to ensure a smooth transition. "Nadav has an incredibly strong track record of operation
- EULAR News: Acelyrin's IL-17A Blocker Performs Well in PsAhttps://practicaldermatology.com/news/eular-news-acelyrins-il-17a-blocker-performs-well-in-psa/2461657/ACELYRIN, INC.’s IL-17A blocker izokibep demonstrated higher levels of response across psoriatic arthritis disease manifestations, according to 46-week data from a global Phase 2 trial of izokibep in psoriatic arthritis (PsA). Izokibep is a small pr
- Dr. James G. Krueger Joins ASA’s Board of Directorshttps://practicaldermatology.com/news/dr-james-g-krueger-joins-asas-board-of-directors/2461651/James G. Krueger, MD, PhD, will join the American Skin Association’s (ASA) Board of Directors. Dr. Krueger is the David Martin Carter Professor in Clinical Investigation and Head of the Laboratory for Investigative Dermatology at The Rockefeller University in&
- Aquavit Files Additional IND for New Toxin for Palmar Hyperhidrosishttps://practicaldermatology.com/news/aquavit-files-additional-ind-for-new-toxin-for-palmar-hyperhidrosis/2461625/Aquavit Holdings is asking the US Food and Drug Administration for an additional IND for DTX-024, a treatment of palmar hyperhidrosis using the company’s patented microchannel technology. DTX-024 is a highly purified and clinically tested injectable neuromodulator derived fr
- Molluscum Contagiosum Update: Two New Treatments Come Down the Pikehttps://practicaldermatology.com/news/molluscum-contagiosum-update-two-new-treatments-come-down-the-pike/2461621/Thanks to a busy pipeline, treating molluscum contagiosum may get easier. The U.S. Food and Drug Administration (FDA) accepted Novan’s New Drug Application (NDA) for Berdazimer Gel, 10.3% for the treatment of molluscum contagiosum with a Prescription Drug User Fee A